Do you have kidney or bladder cancer. You may be able to participate in a research study to find out if the investigational drug REGN10597 is safe, tolerable, and effective in treating kidney and bladder cancer.

Do you have bladder cancer and have had your bladder removed? If so, you may be able to take part in a research study to determine if patients need additional treatment called immunotherapy to prevent cancer from coming back.

Do you have bladder cancer that has spread to nearby tissue or other parts of the body? You may be able to participate in a research study to find out if the investigational drug disitamab vedotin alone or with pembrolizumab works to treat bladder cancer.

Have you been diagnosed with Multiple Myeloma? Have you received idecabtagene vicleucel (ide-cel (Abecma)) CAR-T treatment? If so, you may be able to take part in a research study looking at for how long a new drug called iberdomide will keep Multiple Myeloma under control (in remission).

This study aims to understand how a person's race and where they live affect the quality of breast cancer care they receive. We invite Black and/or African American breast cancer patients and survivors from specific areas of North Carolina to participate in a virtual focus group. The purpose of this focus group is to get your feedback about maps and other tools our team has created to show how breast cancer care quality varies around the state and by race. We also want to hear your experiences seeking care in your area, and your ideas about possible reasons behind the patterns in your area.

Collect Biospecimens from subjects who are newly diagnosed with Acute Myeloid Leukemia (AML)

Have you been diagnosed with Blood Cancer. If so, you may be able to take part in a research study looking at the safety of giving a new drug called AK117 to patients with Leukemia

Have you been diagnosed with s Cutaneous (skin) Lymphoma? If so this could be a good study for you to paticipate in. One of the primary goals of the USCLC is to establish a registry of patients with cutaneous lymphoma in the United States. Such a registry would collect information such as the specific cutaneous lymphoma diagnosis, stage of disease, treatments used, and response to treatments. This information will collected on an online Institutional Review Board (IRB)-approved database/registry of patients from all sites. We hope that this will allow providers to better understand this rare disease by looking at data from many patients. We hope ultimately will include all the patients with cutaneous lymphoma across the United States

Have you been histologically or cytologically confirmed to have Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapies? If so, you may be able to participate in a research study seeking to find out if Amivantamab Monotherapy and/or Amivantamab in Addition to Standard of Care Therapeutic Agents can be an effective traetment.

Have you been diagnosed with Chronic Myeloid Leukemia, have a T315I mutation, and previously treated with at least two tyrosine kinase inhibitors (TKIs)? You might be able to participate in this study.